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Abstract
Background: Nine out of ten deaths from malaria occur in sub-Saharan Africa. Various control measures have achieved
some progress in the control of the disease, but malaria is still a major public health problem in Africa. Randomized
controlled trials (RCTs) are universally considered the best study type to rigorously assess whether an intervention is
effective. The study reported here provides a descriptive analysis of RCTs reporting interventions for the prevention and
treatment of malaria conducted in Africa, with the aim of providing detailed information on their main clinical and
methodological characteristics, that could be used by researchers and policy makers to help plan future research.
Methods: Systematic searches for malaria RCTs were conducted using electronic databases (Medline, Embase, the
Cochrane Library), and an African geographic search filter to identify RCTs conducted in Africa was applied. Results
were exported to the statistical package STATA 8 to obtain a random sample from the overall data set. Final
analysis of trial characteristics was done in a double blinded fashion by two authors using a standardized data
extraction form.
Results: A random sample of 92 confirmed RCTs (from a total of 943 reports obtained between 1948 and 2007) was
prepared. Most trials investigated drug treatment in children with uncomplicated malaria. Few trials reported on
treatment of severe malaria or on interventions in pregnant women. Most trials were of medium size (100-500
participants), individually randomized and based in a single centre. Reporting of trial quality was variable. Although
three-quarter of trials provided information on participants’ informed consent and ethics approval, more details are
needed.
Conclusions: The majority of malaria RCT conducted in Africa report on drug treatment and prevention in
children; there is need for more research done in pregnant women. Sources of funding, informed consent and trial
quality were often poorly reported. Overall, clearer reporting of trials is needed.
Background
Almost 90% of all malaria cases occur in sub-Saharan
Africa, with the major burden on children under five
years of age and pregnant women [1]. Current measures
to control malaria show some degree of success: more
than one-third of malaria-endemic countries, including
nine African countries, have reported a reduction of
malaria cases of >50% between 2000 and 2008 [2,3].
However, malaria remains a major public health
problem in Africa, and more work is needed to evaluate
new interventions and those currently in use.
Randomized controlled trials (RCTs) provide unbiased
estimates of the effects of an intervention [4], and allow
formal synthesis of results between trials in systematic
reviews and meta-analysis. Up-to-date information on
completed, ongoing, and planned RCTs for malaria inter-
ventions is needed to inform policy and to plan future
research, but an overview of these RCTs is not currently
available. Although several studies [5-7] have reported on
different methodological aspects of RCTs conducted in
Africa, and on their relevance to the burden of disease of
the local populations, a comprehensive analysis of clinical
and methodological characteristics of malaria RCTs run
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in Africa has been lacking. This comprehensive evalua-
tion can help determine which areas of malaria research
have been predominant or overlooked, and assess
whether RCTs have effectively covered the health needs
of the whole population. In addition, an examination of
the methodological characteristics and quality of RCTs
can be used to highlight training needs for trialists and
other issues related to ethical approval and participants’
consent. For this analysis a database of RCTs of malaria
prevention and treatment run in Africa was prepared and
the clinical characteristics and methodology of these
trials were assessed and reported in this article.
This work was undertaken under the umbrella of the
Pan African Clinical Trials Registry [8], which was
established with support from the European and
Developing Countries Clinical Trials Partnership.
Methods
On 31st August 2007 a database of malaria trials pre-
pared for the Cochrane Infectious Diseases Group
(CIDG) was searched to identify RCTs conducted in
Africa. The CIDG malaria trials database is populated
from searches in Medline, Embase, Cochrane CENTRAL
and LILACS, to identify RCTs. The search strategy
included the terms “malaria”, “plasmodium”, and the
Cochrane sensitive filter to identify RCTs [9]. Trials
conducted in African countries were identified by apply-
ing an African geographic search filter [10]. These
records were exported into an MS Excel spreadsheet
and categorized using the following variables: malaria
prevention or treatment, type of intervention (drugs,
bed nets, nutritional supplements, vaccines), type of par-
ticipants (adults, children, pregnant women) and type of
malaria (asymptomatic, uncomplicated or severe).
Records were then exported to the statistical package
STATA 8 to obtain a random sample from the overall
data set. The random sample was meant to be 10% and
intentionally over-sampled to ensure that there would
be sufficient RCTs for data extraction. To ensure the
random sample was broadly representative of the initial
dataset, variables from abstracts of the records included
in the two sets were extracted and compared their fre-
quencies. Two authors (VL and AG) then screened the
abstracts of the articles included in the random sample
in a blinded fashion to identify RCTs. A third author
(NS) acted as an arbiter in case of disagreement. Full
articles for the confirmed RCTs were retrieved. A data
extraction form was developed and pilot-tested on ten
articles. VL and AG extracted data using this standar-
dized data extraction form and a third author (NS)
resolved disagreements when these arose. The full set of
variables extracted from these trials is shown in Addi-
tional file 1. One author (VL) examined the data extrac-
tion forms and entered data in MS Excel for final
analysis. Results are presented as frequency of variables,
calculated in MS Excel.
Results
Search results
A total of 1,814 records describing malaria trials between
1948 and August 2007 was identified; 943 articles (51.9%)
were reports of trials in Africa (Figure 1). A random sam-
ple of 176 records was drawn from the total dataset. After
reading each available abstract from the random sample,
and excluding 14 reports (non-RCTs or not taking place
in Africa), seventy-four studies described as RCTs were
considered eligible for inclusion in the analysis A further
37 records were not eligible as they were not RCTs, and
for a further 51 records it was not possible to clearly deter-
mine eligibility from the abstract. Two authors (VL and
AG) read the full text of these 51 “unclear” records and a
further 18 RCTs were identified for inclusion. The final
number of RCTs included in the analysis was 92 (52.2% of
the random sample of 176); these RCTs were run between
1977 and 2007. The full text of these 92 trials was
retrieved for further analysis.
Location of trials, principal investigators and funding
Figure 2 shows the location of the trials included in the
final analysis. RCTs took place in a total of 27 African
countries. Countries hosting more than five trials were
Kenya (13), Nigeria (10), Tanzania (10), the Gambia (8),
and Ghana (6). Other African countries hosted between
one and four RCTs. Over 60% of RCTs (n = 58) were
conducted in rural areas, 27 were run in town and cities,
one trial had both urban and rural sites, and for 5 of
them the location was unclear.
The principal investigator (PI) was not clearly declared
in every article. When the address of the PI was not
reported the location of the corresponding author was
used. Thirty-seven PIs lived in African countries: Nigeria
(8), Sudan (4), Kenya (4), Tanzania (3), Burkina Faso (2),
Ethiopia (2), Ghana (2), Mozambique (2), the Gambia (2),
Uganda (2), Benin (1), Cameroon (1), Guinea Bissau (1),
Madagascar (1), Niger (1), and Togo (1). Forty-two PIs
lived in non-African countries with most PIs based in the
USA (10) and the UK (9), Denmark (5) and Switzerland
(5). It was not possible to determine the country of resi-
dence of the PI in 13 reports. Source of funding was not
reported in one fifth of the trials (n = 19) and even when
reported, it was not always possible to determine exactly
the nature of the funding agency and the relative contri-
butions of governments, non-government organizations
and pharmaceutical companies.
Characteristics of included trials
Fifty-three of the 92 included trials evaluated a treat-
ment intervention for malaria and 38 trials reported on
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malaria preventive measures; one trial reported both
prevention and treatment.
For the 53 trials of malaria treatment, 44 reported on
treatment of acute uncomplicated malaria, seven
reported on severe malaria, one on asymptomatic
malaria and one report was unclear. All but one of the
trials reported on a drug intervention.
Of the 38 trials of malaria prevention, 10 reported on
drug interventions and 10 on the use of bed nets or
other physical barriers, six reported on nutritional sup-
plements, six on vaccines, five on combinations of nutri-
tional supplements and drugs and one trial reported on
a combination of bed nets and drug prophylaxis.
The demographic characteristics of the participants in
the 92 trials are shown in Figure 3.
Sample size and methodological quality
Ninety trials were parallel randomized and two had a
crossover design. Seventy-two trials were randomized at
the individual level, 14 trials were cluster randomized
(mostly describing large scale interventions, such as use
of bed nets or nutritional supplements) and for four
trials the level of randomization was unclear. Two-thirds
(62 of the total) compared two interventions, 16 trials
compared three interventions, and 14 compared four or
more interventions.
Assessment of the methodological quality of RCTs
was based on four items: allocation generation, alloca-
tion concealment, blinding and loss to follow up. RCTs
from the random sample published between 1997 and
2007 were considered for this analysis (n = 60). Results
are shown in Table 1. Allocation generation was con-
sidered adequate (as done by using a random numbers
table or electronically generated) in 35 RCTs, but
methods were not reported in 21 RCTs. Many RCTs
(36) did not mention methods of allocation conceal-
ment or of blinding of participants or intervention pro-
viders (27). Loss to follow up was accounted for in
most RCTs (49).
The number of participants included in the 72 indivi-
dually randomized malaria trials is shown in Figure 4.
The lowest number of participants was 12 (two RCTs
both reporting on malaria drug treatment in adults), and
the highest number of participants was 22,000 (a study of
nutritional supplements in malaria prevention in children
in Ghana) with a median of 210 participants per trial.
Figure 1 PRISMA Flowchart of search results and assessment.
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Ethics and informed consent
Of the 92 included RCTs, 35 had been approved by a
national ethics committee, 31 had received the approval
of both a national and an international ethics commit-
tee, and 26 did not report any detail about ethical
approval. Older RCTs were more likely not to report on
ethical approval: of the 33 studies run between 1977
and 1997 (the first 20 years of our random sample),
over half (17) did not mention this characteristic, in
contrast to only nine out of 59 that were run between
1998 and 2007.
Thirty-nine RCTs reported that participants’ informed
consent had been obtained but did not specify any
details, 21 reported obtaining written consent, five
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Figure 3 Demographic characteristics of trials’ participants.
Table 1 Assessment of trial quality for African malaria









Blinding 23 27 10
Loss to follow up 49 n/a 11
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reported oral consent and in three cases both oral and
written consent was obtained. Participants’ informed
consent was not reported in 25 RCTs.
Discussion
This study was designed to obtain information on the
clinical and methodological characteristics of RCTs con-
ducted in Africa on malaria interventions. This informa-
tion is needed to plan and implement future malaria
clinical trials, to suggest research areas that may have
been overlooked, and to point to methodological aspects
that need to be addressed when planning future
activities.
This was a novel analysis and no similar comprehen-
sive study of African malaria RCTs has been done
before.
More than half of the total malaria trials identified in
the initial search were conducted in Africa, a finding
consistent with the high local burden of disease but also
indicative of high levels of research activity, as shown
for other infectious and parasitic diseases affecting
Africa [5]. More RCTs were run in large countries such
as Nigeria, Tanzania or Kenya, but the size of a country
or its population were not directly indicative of num-
bers: smaller countries (Ghana, the Gambia) also con-
tributed many RCTs, possibly as a result of a better
health infrastructure or the presence of well established
research institutions (such as the UK Medical Research
Council Laboratories based in the Gambia). A Wellcome
Trust report [11] similarly reported a high number of
malaria research studies and publications between 1995
and 1997 originating from Kenya, Tanzania, Nigeria and
the Gambia.
Approximately half of PIs in the studies analysed were
based in African countries (mainly Nigeria, Kenya,
Sudan and Tanzania); it is possible that some PIs were
of African origin but resident and working outside the
continent, as it has been reported for HIV/AIDS
researchers [12] Most authors based outside Africa were
resident in the USA and UK, but several had an address
in Switzerland or in Denmark, smaller countries with a
long-standing tradition of international collaborations.
The presence of locally based researchers has been
found to positively affect the local development of skills
and training [7,12] and is in general correlated to
research relevant to the particular country.
Information about trial funding and sponsorship was
not included, or was poorly reported, in many published
trials, and for this reason it has not been included in the
final analysis. It has previously been shown that almost
all African HIV/AIDS trials are led and funded by inter-
national organizations [10] and if the same is true of
malaria trials, this can explain why many authors of trial
reports are based outside Africa. The nature of funding
agencies is also likely to influence priorities for trials
and research receiving funding from private industry,
for instance, was found to be associated with reduced
emphasis on diseases relevant to Africa [7].
Clinical characteristics
The majority of RCTs reported on drug treatment of
children suffering from uncomplicated malaria, in agree-
ment with the high burden of malaria in the under-fives
[13] and with the development and testing of novel drug
regimens such as artemisinin-based combination therapy
(ACT). ACT was included in World Health Organiza-
tion malaria guidelines in 2006 [14,15], prompting many
African countries to run clinical trials in order to assess
the best drug combination to be included in national
policies.
Few RCTs investigated treatment of severe malaria or
interventions in pregnant women. The scarcity of clini-
cal trials for severe malaria was noted in a previous
study [16], showing that fewer than 10,000 patients have
been included in RCTs despite approximately ten mil-
lion cases of severe malaria occurring annually. Clinical
studies in severe malaria are considered difficult to plan
and execute [17], and are often characterized by slow
enrolment, requiring many sites and several years for
completion. Also, after the successful introduction of
ACT regimens, patients with severe malaria may simply
not be found any more in some countries, as reported
in Vietnam [18].
The paucity of RCTs assessing interventions to pre-
vent or treat malaria in pregnancy is a cause for con-
cern, as pregnant women are especially vulnerable to
Plasmodium and the infection can also affect the
unborn child. The scarcity of human studies on the
pharmacokinetics, safety and efficacy of anti-malarials in
pregnancy has been described previously [19,20], and
the need for more well-designed and clearly reported
RCTs in pregnant women was highlighted in a recent
Cochrane review [21]. Pregnant women are routinely
excluded from clinical trials involving the general popu-
lation to avoid harm to them or to their unborn baby,
but when coupled with few clinical trials with only






















Figure 4 Trials size - Number of participants randomized.
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pregnant women as participants, this limits the amount
of information available on drug safety and effectiveness.
It must be noted that recent research initiatives, such as
the Malaria in Pregnancy (MiP) Consortium [22], aim to
address this lack of knowledge, and several trials to eval-
uate interventions for the prevention and treatment of
malaria in pregnancy, sponsored by this or other organi-
zations, are currently ongoing.
Trial methodology
The methodological quality of malaria RCTs published
in the decade 1997-2007 was assessed. These RCTs
were likely to have been conducted after the publica-
tion in 1996 of the original CONSORT guidelines for
reporting RCTs [23]. The quality of reporting was not
consistent among its different domains: loss to follow-
up was accounted for in the majority of RCTs, but
allocation concealment was mostly unclear, and gen-
eration of allocation sequence and blinding were also
not clearly reported or altogether not mentioned in a
large proportion of malaria RCTs. Similar poor report-
ing has been widely reported for RCTs in different
medical areas [24,25], not only in those conducted in
the first few years after the publication of the CON-
SORT guidelines but also for recent ones [26,27]. Sub-
optimal trial reporting is a worldwide concern and
indeed a recent analysis of HIV/AIDS trials [12] found
that African trials had better reporting for allocation
concealment and for random generation than North
American trials. Prospective trail registration accompa-
nied by education of trialists about the CONSORT
(through instructions provided by trial registers at the
time of initial registration) can help.
Ethics, informed consent
Approximately three-quarters of RCTs reported on
approval by an ethics committee and a similar percen-
tage included information on participants’ consent to
the procedure. Reporting of approval by an ethics
committee markedly improved over time and the vast
majority of RCTs run in the last decade had received
local or international ethics approval. This is an
encouraging result overall, and several trial reports
also provided a detailed description of the consent pro-
cedure; however, 38 reports stated consent had been
obtained, but did not provide any details. Similarly, in
a recent systematic review of registered trials of
malaria, tuberculosis and HIV/AIDS [28], informed
consent was reported in 58% of trials. When informa-
tion is not clearly reported or lacking altogether, the
possibility arises that informed consent was not always
“truly informed” or “truly voluntary”, perhaps because
of low literacy levels and other socio-economic and
cultural factors, as suggested in a recent analysis of
trials conducted in sub-Saharan Africa [29]. Studies
from Malawi [30,31] reported that participation into
research studies was linked to the hope of benefiting
from the material and monetary incentives available,
including the ancillary care provided by clinical trials.
Incomplete reporting or consent which is not truly
informed, (especially where resources are limited) is a
problem that needs to be urgently addressed, possibly
by strengthening national guidelines on clinical
research including ethics review.
Trial reporting and the need for prospective registration
A recurrent finding in the present analysis was that in
many trials, several characteristics were suboptimally
reported. Details about funding, PI location, and
informed consent were often missing or, if mentioned,
were difficult to interpret. Similarly, reporting on the
methodology used in many trials was poor. This finding
is not unique for malaria RCTs or for trials conducted
in Africa, but the problem of difficult interpretation and
poor compliance with the CONSORT statement [23,32]
needs to be addressed to allow for sound conclusions
and evidence-based decision making. There is need for
education of trialists about the CONSORT statement as
well as stringent requirements for publication in medical
and scientific journals.
Strengths of this study include a comprehensive search
of the literature using multiple databases and randomly
sampling from the total dataset, to ensure a high degree
of representativeness. In addition, both the eligibility
process and data extraction were conducted by two
independent investigators and a third provided quality
evaluation. Despite this, findings are limited by the fact
that only access to reported data was possible. It is likely
that additional trials have been conducted which have
not been presented at a conference or reported in the
literature [33]. Prospective trial registration ensures that
essential information is publicly available before a trial
begins, through a set of pre-agreed standards. It also
provides a unique trial registration number that makes
it easy to identify a specific trial and minimize duplica-
tion. Within Africa, the Pan African Clinical Trials Reg-
istry [8] is a new initiative that aims to prospectively
register all clinical trials run in Africa [34]. Prospective
registration of African RCTs, by ensuring that trials
authors comply with a series of methodological items,
will help improve trial quality, reduce publication bias
and facilitate regular updating of analyses similar to the
one presented here. Providing regulatory bodies in Afri-
can countries take steps to encourage trialists to register
on the Pan African Clinical Trials Registry, unnecessary
duplication of research may be avoided, and better har-
monization achieved between ethics, regulatory and
registration bodies.
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Conclusions
Most malaria RCTs run in Africa investigated treatment,
predominantly with drugs, in children with uncompli-
cated malaria. Few trials reported on treatment of severe
malaria or on interventions in pregnant women, but
new initiatives and several new trials are addressing
interventions in pregnant women. Most trials were of
medium size (100-500 participants), individually rando-
mized and based in a single centre. Reporting of metho-
dological quality of trials was often unclear or
inconsistent among its components. Although three-
quarter of trials provided information on participants’
informed consent and ethics approval, more details and
clear reporting are needed. Prospective trial registration
will help. These findings are valuable because they pro-
vide baseline knowledge of malaria trials that should
facilitate the planning and implementation of future
trials of malaria interventions in Africa.
Additional material
Additional file 1: Data extraction variables for each trial included in
the analysis. A table listing details of the trial characteristics that were
extracted from each report included in the article.
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